Form 4: EyePoint Pharmaceuticals CEO Jay Duker Reports Stock Transactions
SEC Form 4 Filing
EyePoint Pharmaceuticals' CEO, Jay Duker, reports acquisition and disposal of company stock and restricted stock units.
Summary
- On July 10, 2024, Jay S. Duker, the President and CEO of EyePoint Pharmaceuticals, engaged in transactions involving the company's common stock and restricted stock units.
- Duker acquired 16,666 shares of common stock through the exercise of restricted stock units at a price of $0.00.
- Simultaneously, 8,059 shares were withheld by the issuer to cover tax obligations related to the vesting of these restricted stock units at a price of $8.69.
- Following these transactions, Duker directly owns 38,027 shares of common stock.
- Additionally, Duker indirectly owns 22,500 shares through a family trust.
- He also directly owns 33,334 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral report on stock transactions by an insider, with no inherent positive or negative implications.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, like the CEO, who trade in their company's stock. It provides transparency to the market regarding insider activity.
Stakeholder Impact
- The transactions may have a minor impact on shareholders by slightly diluting the stock.
Key Dates
| Date | Description |
|---|---|
| 07/10/2024 | Date of stock and restricted stock unit transactions. |
| 07/10/2024 | Vesting start date for restricted stock units in three annual installments. |
| 07/12/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.